ITEM VIEW

Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A meta-analysis of randomized controlled treatment trials

dc.contributor.authorFineberg N.A.
dc.contributor.authorStein D.J.
dc.contributor.authorPremkumar P.
dc.contributor.authorCarey P.
dc.contributor.authorSivakumaran T.
dc.contributor.authorVythilingum B.
dc.contributor.authorSeedat S.
dc.contributor.authorWestenberg H.
dc.contributor.authorDenys D.
dc.date.accessioned2011-05-15T15:59:17Z
dc.date.available2011-05-15T15:59:17Z
dc.date.issued2006
dc.identifier.citationInternational Clinical Psychopharmacology
dc.identifier.citation21
dc.identifier.citation6
dc.identifier.issn2681315
dc.identifier.other10.1097/01.yic.0000215083.57801.11
dc.identifier.urihttp://hdl.handle.net/10019.1/11098
dc.description.abstractSmall studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive-compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory. This paper reports a meta-analysis of existing double-blind randomized placebo-controlled studies looking at the addition of the second-generation antipsychotic quetiapine in such cases. Three studies fulfilled the inclusion criteria. Altogether 102 individuals were subjected to analysis using Review Manager (4.2.7). The results showed evidence of efficacy for adjunctive quetiapine (<400 mg/day) on the primary efficacy criterion, measured as changes from baseline in total Yale-Brown Obsessive Compulsive Scale scores (P=0.008), the clinical significance of which was limited by between-study heterogeneity. The mechanism underlying the effect may involve serotonin and/or dopamine neurotransmission. © 2006 Lippincott Williams & Wilkins, Inc.
dc.subjectplacebo
dc.subjectquetiapine
dc.subjectserotonin uptake inhibitor
dc.subjectadult
dc.subjectarticle
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdouble blind procedure
dc.subjectdrug efficacy
dc.subjectdrug resistance
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectObsessive-compulsive disorderen_ZA
dc.subjectpriority journal
dc.subjectrandomized controlled trial
dc.subjectscoring system
dc.subjecttreatment outcome
dc.subjectAdult
dc.subjectAntipsychotic Agents
dc.subjectDibenzothiazepines
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectObsessive-compulsive disorderen_ZA
dc.subjectPsychiatric Status Rating Scales
dc.subjectRandomized Controlled Trials
dc.subjectSerotonin Uptake Inhibitors
dc.subjectTreatment Outcome
dc.titleAdjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A meta-analysis of randomized controlled treatment trials
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW